Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Decreases By 13.7%

Entera Bio Ltd. (NASDAQ:ENTX) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 86,100 shares, a drop of 13.7% from the February 28th total of 99,800 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 114,700 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Tuesday, March 18th.

Hedge Funds Weigh In On Entera Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Parkman Healthcare Partners LLC lifted its holdings in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the last quarter. Perigon Wealth Management LLC acquired a new position in Entera Bio during the 4th quarter valued at about $325,000. Northern Trust Corp purchased a new stake in Entera Bio in the fourth quarter valued at about $450,000. Finally, Knoll Capital Management LLC boosted its holdings in Entera Bio by 51.5% in the fourth quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock worth $12,470,000 after acquiring an additional 2,000,000 shares in the last quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Price Performance

Shares of ENTX stock opened at $1.64 on Friday. The stock’s 50-day moving average is $2.08 and its 200 day moving average is $2.01. Entera Bio has a 1-year low of $1.41 and a 1-year high of $3.35. The company has a market cap of $74.49 million, a P/E ratio of -6.31 and a beta of 1.47.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. On average, analysts anticipate that Entera Bio will post -0.28 EPS for the current year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.